Virax Biolabs Secures ISO Certifications to Propel IVD Development and Clinical Validation in the U.S.

Virax Biolabs Achieves ISO Certifications

Virax Biolabs Group Limited, known for its focus on diagnostic technologies, announced that its subsidiary, Virax Biolabs (UK) Limited, has successfully obtained ISO 13485:2016 and ISO 9001:2015 certifications. These quality management system certifications were awarded by Lloyd’s Register Quality Assurance (LRQA), marking a significant step in Virax's strategic roadmap for post-acute infection syndromes (PAIS).

Significance of the Certifications

With ISO 13485:2016, Virax bolsters its capability in designing and developing immunological assay components and kits. This standard is particularly critical for companies involved in medical devices and diagnostics, as it ensures regulatory compliance and the reliability of products. On the other hand, ISO 9001:2015 is a more generalized standard applicable across various industries, helping maintain consistency and quality in products and services. Together, these certifications provide a robust foundation for Virax's future developments in regulated in vitro diagnostic (IVD) technologies and supports ongoing clinical validation activities in the U.S.

The significance of these achievements transcends regulatory compliance; they assert Virax’s commitment to enhancing research and development frameworks that are foundational for diagnosing conditions such as Long COVID. Virax aims to develop a transatlantic T cell immune-profiling platform that includes clinical and regulatory benchmarks in both the UK and the U.S.

Advancing Clinical Validation Efforts

Virax Biolabs is simultaneously advancing its clinical validation work in the United States. Recently, the company signed a Research Services Agreement with Emory University's ADJUST Center to facilitate clinical studies focusing on ViraxImmune™, a diagnostic test aimed at immune profiling for individuals suffering from Long COVID. Through this partnership, Emory will conduct laboratory testing and analysis that will inform the regulatory planning and commercial rollout of Virax's diagnostic tests.

James Foster, the Chairman and CEO of Virax, emphasized the importance of these certifications as crucial milestones, reflecting the hard work undertaken by the team to maintain high-quality systems essential for the development of immunological assays. He stated, “This achievement not only strengthens our operational framework for IVD development but also enhances our credibility as we expand our clinical programs and testing pathways.”

Optimizing Quality Systems

The recent ISO certifications are not just bureaucratic achievements; they represent a commitment to disciplined development and stringent controls over critical assay components and documentation processes. These aspects are crucial in supporting validation activities and scaling up operations in compliance with applicable regulations. Virax places high importance on maintaining a quality-managed developmental approach that enables it to build a strong evidential base through clinical programs both in the UK and U.S.

In a landscape where diagnostic precision is paramount, securing these ISO certifications positions Virax favorably in the biotech sector, particularly in developing solutions for post-acute infections. The certifications enhance the credibility of Virax's products, providing a significant advantage as the company navigates a competitive market focused on innovative health solutions.

Future Prospects

As Virax progresses, it will continue to assess potential U.S. laboratory-based testing services and explore pathways that may include laboratory-developed tests (LDTs). With a clear focus on innovation and quality, Virax Biolabs is poised to make substantial contributions to the field of immunology and diagnostics, especially for chronic conditions linked to immune dysregulation.

For further information, visit Virax Biolabs Official Website.